Preliminary Clinical Experience with Ocrelizumab, a New Recombinant Humanized Monoclonal Antibody for Multiple Sclerosis

2020 ◽  
Vol 37 ◽  
pp. 101590
Author(s):  
Ameneh A. Baghestani ◽  
Ghadah A. Al-Sharif ◽  
Derk W. Krieger
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibody ◽  
Clinical Experience ◽  
Humanized Monoclonal Antibody

scholarly journals tocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical case)

2020 ◽  
Vol 12 (3) ◽  
pp. 90-93
Author(s):  
D. D. Avdoshina ◽  
A. G. Dyachkov ◽  
D. A. Gusev
Keyword(s):  
Monoclonal Antibody ◽  
Inflammatory Response ◽  
Clinical Experience ◽  
Interleukin 6 ◽  
Clinical Case ◽  
Saint Petersburg ◽  
Humanized Monoclonal Antibody ◽  
Anticytokine Therapy ◽  
Human Receptor

Improving the approaches to treating COVID-19 infection opens up the possibility for using previously known groups of drugs that demonstrate their effectiveness in the pathogenetic treatment of this disease. Significant clinical experience in the field of treatment of COVID-19 have been accumulated in Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia. The case study demonstrates the timeliness and effectiveness of anticytokine therapy with COVID-19, the possibility of using a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (IL-6) (tocilizumab).

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab

2018 ◽  
Vol 24 (6) ◽  
pp. 811-813 ◽  
Author(s):  
Benoit Meunier ◽  
Audrey Rico ◽  
Julie Seguier ◽  
Clemence Boutiere ◽  
Mikael Ebbo ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibody ◽  
Adverse Event ◽  
Hemolytic Anemia ◽  
The Third ◽  
Disease Modifying Therapy ◽  
Humanized Monoclonal Antibody ◽  
Relapsing Remitting ◽  
Life Threatening ◽  
Disease Modifying

Background: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Objective: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. Methods: Case report. Results: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course. Conclusion: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.

scholarly journals Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis

2017 ◽  
Vol 23 (10) ◽  
pp. 1424-1427 ◽  
Author(s):  
Robert W Foley ◽  
Nathan T Tagg ◽  
Matthew K Schindler ◽  
Kaylan M Fenton ◽  
Daniel S Reich ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Cell Migration ◽  
Aseptic Meningitis ◽  
Cns Infection ◽  
T Cell Migration ◽  
Humanized Monoclonal Antibody ◽  
The Central Nervous System

Natalizumab is a recombinant humanized monoclonal antibody that decreases T-cell migration into the central nervous system (CNS) through α4 integrin:adhesion-molecule inhibition, thereby increasing the risk for opportunistic CNS infection. Herein, we report a case of infusion-associated aseptic meningitis in a patient receiving natalizumab.

scholarly journals Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application

2020 ◽  
pp. 88-94
Author(s):  
N. Yu. Lashch
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibody ◽  
Humanized Monoclonal Antibody ◽  
Complement Dependent Cytotoxicity ◽  
Dependent Cell ◽  
Magnetic Resonance Imaging Mri ◽  
Antibody Preparations ◽  
Brain And Spinal Cord ◽  
The Brain

Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative disease with a multifactorial etiology of development. MS in most cases has a wave-like course (periods of exacerbations and remissions), over time, the disease becomes progressive, which worsens the quality of life of patients. The drugs disease-modifying therapies (DMT) has been actively used in clinical practice for more than 30 years to prevent exacerbations and progression of MS. In patients with MS, in which the disease occurs with frequent exacerbations and signs of radiological activity of the demyelinating process, according to magnetic resonance imaging (MRI) of the brain and spinal cord, it is recommended to use monoclonal antibody preparations. The only drug registered for the treatment of primary progressive MS is ocrelizumab. In addition, ocrelizumab is indicated for patients with remitting and secondary progressive MS. Ocrelizumab is a humanized monoclonal antibody that selectively depletes a population of CD20+ B cells. The article presents data from clinical studies of OPERA I and OPERA II and describes a clinical case from the practice of a neurologist. Depletion of the B cell population is achieved by several mechanisms, including antibody-dependent cell-mediated phagocytosis, antibody-dependent T cell-mediated cytotoxicity, complement-dependent cytotoxicity, and apoptosis induction. The issues of efficacy and safety of ocrelizumab therapy in patients with MS are considered.

scholarly journals Clearance Kinetics and External Dosimetry of 131I-Labeled Murine and Humanized Monoclonal Antibody A33 in Patients with Colon Cancer: Radiation Safety Implications

2009 ◽  
Vol 96 (5) ◽  
pp. 550-557 ◽  
Author(s):  
Lawrence T. Dauer ◽  
Daniel C. Boylan ◽  
Matthew J. Williamson ◽  
Jean St. Germain ◽  
Steven M. Larson
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Radiation Safety ◽  
Humanized Monoclonal Antibody ◽  
Clearance Kinetics

scholarly journals Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4127
Author(s):  
Aline de Cristo Soares Alves ◽  
Franciele Aline Bruinsmann ◽  
Silvia Stanisçuaski Guterres ◽  
Adriana Raffin Pohlmann
Keyword(s):  
Monoclonal Antibody ◽  
Physicochemical Characterization ◽  
Vascular Endothelial ◽  
Organic Nanoparticles ◽  
Humanized Monoclonal Antibody ◽  
Angiogenesis Process ◽  
Endothelial Growth Factor ◽  
Drug Pharmacokinetics

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.

Sign in / Sign up

Export Citation Format

Share Document